Dr Alison Todd has extensive experience within the pharmaceutical industry where she developed several novel molecular analytical technologies which have been used for basic research, preclinical/clinical drug development and in vitro diagnostics. Her specific areas of scientific expertise include nucleic acid chemistry, particularly target amplification and catalytic DNA technologies, and the biology of cancer and viral diseases. Prior to founding SpeeDx, Alison was a Senior Research Director at Johnson and Johnson Research Pty Limited, Sydney. Alison is an inventor on 18 patents/patent applications and her techniques have been used for molecular monitoring in nine international clinical trials for patients with HIV, leukaemia and various solid tumours. She has successfully championed multiple inventions through to product commercialization in various fields. Alison studied at the University of Sydney, obtaining a BSc (Hons 1st Class) and later completed a PhD within the Faculty of Medicine at the same university. Alison maintains an active involvement within the academic community and holds an adjunct appointment as Senior Visiting Fellow at the University of New South Wales.
Alison will present on: "Highly multiplex qPCR tests using a combination of PlexPrimers and PlexZymes".